Results 161 to 170 of about 1,913 (212)

Ocular Drug Delivery: Emerging Approaches and Advances. [PDF]

Pharmaceutics
Gade S, So Y, Mishra D, Baviskar SM, Assiri AA, Glover K, Sheshala R, Vora LK, Thakur RRS.   +8 more
europepmc   +1 more source

Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang/Tie, and inflammatory pathways. [PDF]

Front Endocrinol (Lausanne)
Zong Y, Qiu S, Zhang H, Wu J, Du J, Kamoi K, Cen Z.   +6 more
europepmc   +1 more source

Twelve-Month Outcomes of Faricimab for Patients with Sub-Optimally Responsive Diabetic Macular Oedema: A Retrospective Single-Centre Study. [PDF]

Clin Ophthalmol
El-Badawi K, Scrivens B, Eke O, Ismail R, Kobayter L, Salvatore S.   +5 more
europepmc   +1 more source

Beyond the injection: delivery systems reshaping retinal disease management. [PDF]

Expert Opin Pharmacother
Rowe LW, Akotoye C, Harris A, Ciulla TA.
europepmc   +1 more source

A Meta-Analysis of the Efficacy and Safety of the 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. [PDF]

Biomedicines
Yeo S, Chung YR, Song JH, Bodaghi B, Touhami S.   +4 more
europepmc   +1 more source

Paraneoplastic syndromes and the retina. [PDF]

Curr Opin Ophthalmol
Zhao CS, Mruthyunjaya P, Narala R.
europepmc   +1 more source

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis [PDF]

Journal of Clinical Medicine, 2021
The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months. Macular edema was resolved in 24 (70.6%) cases.
Gerd U Auffarth,, Febo, Lucy Joanne Kessler, Ramin Khoramnia   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY

Retina, 2023
Purpose: To assess the efficacy of a 0.18 mg intravitreal fluocinolone acetonide (FA) implant (Yutiq, EyePoint Pharmaceuticals, Watertown, MA) as a treatment option for patients with radiation retinopathy-related cystoid macular edema.
Janani, Singaravelu, Zackery B, Oakey, Jacquelyn M, Wrenn, Arun D, Singh   +3 more
openaire   +2 more sources

ANTERIOR MIGRATION OF INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANTS: A CASE REPORT

RETINAL Cases & Brief Reports, 2022
Background/Purpose: To describe management of anterior migration of a fluocinolone acetonide(FAc) intravitreal implant. Methods: A retrospective case report. A 61-year-old man with diabetic macular edema and prior vitrectomy had anterior migration of a FAc implant.
Robert C, Gunzenhauser, Margaret A, Greven, Vishak J, John   +2 more
openaire   +2 more sources